Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Sponsored by Bristol-Myers Squibb
About this study
This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
This first-in-human clinical trial will begin with an exploration of MRTX1719 dose and regimen. As potentially viable regimens are identified, Phase 1b expansion cohorts may be implemented to ensure sufficient safety experience, PK information, compare food effect and relative bioavailability between capsules and tablets, and early evidence of clinical activity are available.
Where this study is enrolling (15)
- Call 480-301-8000
Mayo Clinic
Phoenix, Arizona
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- Call 303-430-2700
Rocky Mountain Cancer Centers, LLP - Oncology
Lone Tree, Colorado
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- Call 000000000
Mayo Clinic
Jacksonville, Florida
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- Call 617-632-6036
Dana-Farber Cancer Institute
Brookline, Massachusetts
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- Call 269-993-6056
Cancer and Hematology Centers of Western Michigan
Norton Shores, Michigan
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
Show all 15 locations
- Call 269-993-6056
The Cancer & Hematology Centers
Grand Rapids, Michigan
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- Call 206-606-4801
Mayo Clinic
Rochester, Minnesota
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- Call 732-235-2465
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- Call 631751050
New york cancer and blood specialists - Oncology
Port Jefferson Station, New York
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- Call 732-235-2465
Perlmutter Cancer Center at NYU Langone Hospital Long Island
Mineola, New York
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- Call 646-608-3792
David H Koch, Memorial Sloan Kettering Cancer Center
New York, New York
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- Call 206-341-1111
Vanderbilt - Ingram Cancer Center
Nashville, Tennessee
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- Call 214-370-1000
Texas Oncology - DFW
Fort Worth, Texas
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- Call 903-579-9800
Texas Oncology, P.A. - Oncology
Tyler, Texas
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- Call 703-280-5390
Virginia Cancer Specialists, PC
Fairfax, Virginia
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
Who can participate
Inclusion criteria
- ✓Histologically confirmed diagnosis of a solid tumor malignancy with homozygous deletion of the MTAP gene detected in tumor tissue.
- ✓Unresectable or metastatic disease.
- ✓Presence of a tumor lesion amenable to mandatory biopsy for pharmacodynamic evaluation at baseline and on-study unless Sponsor-confirmed as medically unsafe or infeasible.
- ✓Age ≥ 18 years.
- ✓Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- ✓Adequate organ function.
Exclusion criteria
- ✕Prior treatment with a PRMT5 or MAT2A inhibitor therapy.
- ✕Active brain metastases or carcinomatous meningitis.
- ✕History of significant hemoptysis or hemorrhage within 4 weeks of the first dose of study treatment.
- ✕Major surgery within 4 weeks of first dose of study treatment.
- ✕History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications.
- ✕Cardiac abnormalities.
- ✕Other protocol-defined Inclusion/Exclusion criteria apply.
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.